Teva Pharmaceutical Industries Ltd. (TEVA) announced the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer or MASCC/International Society of Oral Oncology or ISOO 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.
Lipegfilgrastim and balugrastim are long-acting granulocyte colony-stimulating factors or G-CSF being evaluated for their ability to reduce the duration of severe neutropenia in breast cancer patients undergoing chemotherapy, the company said.
Neutropenia is a condition in which the number of white blood cells is decreased, leaving patients more susceptible to potentially life-threatening bacterial infections.
The company noted that both product candidates have completed phase III clinical trials. In both phase III breast cancer studies the primary endpoint was achieved, demonstrating reduction in the duration of severe neutropenia or DSN in cycle 1, comparable to pegfilgrastim results in both efficacy and safety measures.
The company said that additional data from the phase I, II and III clinical studies of these products, will be presented at the MASCC/ISOO symposium in both oral and poster presentations.
"Teva is committed to advancing these investigational biologic drugs, which are the most advanced of several biologic products that we have in development," said Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical.
For comments and feedback: editorial@rttnews.com